Loading news...
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Molecular Partners AG ( MOLN ) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program November 12, 2025 10:00 AM EST Company Participants Patrick Amstutz - Co-Founder, CEO, Member of Management Board & Director Daniel Steiner - Senior Vice President of Research & Technology Philippe Legenne - Chief Medical Officer & Member of the Management Board Michael Stumpp - Co-Founder, Executive VP of Projects & Member of Management Board Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Michael Nedelcovych - TD Cowen, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the MP0712 update call.
Molecular Partners AG (NASDAQ:MOLN ) Q4 2024 Earnings Conference Call March 7, 2025 8:00 AM ET Company Participants Michael Tobias Stumpp - EVP Projects Patrick Amstutz - Co-Founder & CEO Philippe Legenne - Chief Medical Officer Robert Hendriks - SVP Finance Seth Lewis - SVP Investor Relations, Communications and Strategy Conference Call Participants Jonathan Chang - Leerink Partners Richard Vosser - JPMorgan Michael Nedelcovych - TD Cowen Joris Zimmermann - Octavian Operator Good morning, and welcome to the Molecular Partners Fourth Quarter and Full Year 2024 Results Call. All participants will be in listen-only mode.
Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript
Molecular Partners AG (NASDAQ:MOLN ) Q4 2022 Earnings Conference Call March 10, 2023 8:00 AM ET Company Participants Seth Lewis - Senior Vice President, Investor Relations Patrick Amstutz - Chief Executive Officer Robert Hendriks - Senior Vice President, Finance Conference Call Participants Joe Walton - Credit Suisse Georgi Yordanov - TD Cowen Daina Graybosch - SVB Securities Operator Good day and welcome to the Molecular Partners Publication of Full Year Results 2022 Conference Call. [Operator Instructions] Please note this event is being recorded.
Molecular Partners AG (NASDAQ:MOLN ) Q2 2022 Earnings Conference Call August 25, 2022 8:00 AM ET Company Participants Seth Lewis - SVP of IR Patrick Amstutz - CEO Andreas Emmenegger - CFO Conference Call Participants Georgi Yordanov - Cowen and Company Richard Vosser - JPMorgan Daina Graybosch - SVB Securities Jo Walton - Credit Suisse Zoe Karamanoli - RBC Capital Markets Operator Good day, and welcome to the Molecular Partners Second Quarter 2022 Half Year Report. All participants will be in listen-only mode [Operator Instructions].
Molecular Partners AG (NASDAQ: MOLN) reported on the clinical progress of its antiviral candidate, ensovibep, as part of a presentation with its partner Novartis AG (NYSE: NVS) at the Credit Suisse ESG Forum Switzerland virtual event. Ensovibep is currently being studied in Phase 2 single-arm pilot study in ambulatory patients in the Netherlands; a global Phase 2/3 study in ambulatory patients, in collaboration with Novartis (EMPATHY); and a National Institutes of Health-sponsored global Phase 3 study in hospitalized patients as part of the ACTIV-3 master protocol.
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners.
Global Phase 3 trial designed to investigate safety and efficacy of ensovibep in hospitalized adults with COVID-19 Ensovibep receives U.S. FDA Fast Track Designation for the treatment of COVID-19 in both hospitalized and ambulatory settings ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 13, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that the first patient has been dosed in a new Phase 3 sub-study evaluating ensovibep, as part of the National Institutes of Health's (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership designed to speed development of treatments and vaccine candidates for COVID-19. Molecular Partners also announced that the U.S. Food and Drug Administration (FDA) has granted ensovibep Fast Track designation, which is intended to expedite the development and review of new therapies to treat serious conditions and fill an unmet medical need.
Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 10, 2021. Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the upcoming presentation of four posters with data supporting three of the company's immunotherapy programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting running April 10-15, 2021.